BPC-157 + MK-677 (Ibutamoren) Stack: When to Pick One Over the Stack

The Two Compounds Are Not the Same Kind of Thing

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. FDA's reviewers wrote in July 2026 that its molecular targets have not been identified and its mechanisms 'remain poorly understood' [1]. The tissue-repair effects usually cited for it come from rat studies, and reviews from the main research group describe actions on the nitric oxide system and on blood vessel growth in animals [1][9][10].

MK-677 (ibutamoren mesylate) is not a peptide, and it is not a SARM. It is an oral small molecule that stimulates growth hormone release at the ghrelin receptor; Merck synthesized it in 1995 and discontinued development in 1999 [2]. It raises growth hormone and IGF-1, a single oral dose stays active for about 24 hours, and it has been through randomized trials in healthy older adults, hip-fracture recovery, Alzheimer's disease and obesity [2].

What Human Evidence Exists for BPC-157

A 2026 systematic review searched through June 1, 2026 and found three studies, 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded it should not be used clinically outside ethically approved, regulated, high-quality trials [3]. Those three studies were a retrospective chart review of knee injections (17 patients, 16 reached by phone, no control group, no validated outcome tools) [11], a single-arm pilot in 12 women with interstitial cystitis where 10 of 12 reported complete symptom resolution after one treatment [12], and a safety pilot in 2 adults given 10 mg then 20 mg intravenously [13].

FDA's own review identified five small clinical studies. Besides the three above, they include a 53-person phase 2 trial of BPC-157 enemas versus placebo in mild to moderate ulcerative colitis, which exists only as a meeting abstract; FDA said it has too little detail to judge effectiveness [1]. FDA reported no serious adverse events in the studies it reviewed, but concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or on the skin, and no human pharmacokinetic data for those routes [1]. After rectal enemas, BPC-157 was mostly not detectable in blood, so FDA judged that it appears not to be absorbed systemically by that route [1].

FDA's adverse-event database search through December 4, 2025 turned up three reports, all for injectable product: injection-site redness and swelling lasting nine days, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product. FDA said it cannot tell whether BPC-157 caused these [1]. In 28-day animal toxicity studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised ALT, glucose and triglyceride levels; longer and cancer-risk studies were not available [1].

What Human Evidence Exists for MK-677

MK-677 has randomized trials. They measured IGF-1 and recorded adverse events, and one trial in older hip-fracture patients was stopped early after a congestive heart failure signal [5].

• In 65 healthy adults aged 60 to 81, 25 mg daily for 12 months raised fat-free mass by 1.1 kg while it fell 0.5 kg on placebo, and body weight rose 2.7 kg versus 0.8 kg. Fasting glucose rose about 5 mg/dL (P=0.015) and insulin sensitivity fell. Strength and function did not improve [14].
• In 123 hip-fracture patients given 25 mg daily, the trial was terminated early for a congestive heart failure signal; FDA's summary gives 4 patients (6.5%) on MK-677 versus 1 (1.7%) on placebo. IGF-1 rose 51.4 ng/mL more than placebo and gait speed improved, but most other function measures did not, and the authors called the profile unfavorable in this population [5][2].
• In 161 hip-fracture patients treated for 6 months, IGF-1 rose 84% versus 17% on placebo with no significant functional benefit; serious adverse events were 24% versus 18%, and thrombosis occurred in 4 versus 0 [15][2].
• In 563 patients with mild to moderate Alzheimer's disease, IGF-1 rose 72.9% at 12 months with no effect on any efficacy measure; drug-related adverse events were 35.5% versus 23.9%, and glucose increases 15.4% versus 4.6% [16][2].
• In 24 obese men treated for 8 weeks, IGF-1 rose about 40% and fat-free mass increased, while total and visceral fat did not change and an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks [17].
• In 292 postmenopausal women with osteoporosis, adding MK-677 to alendronate raised femoral neck bone density 4.2% versus 2.5% with alendronate alone, with no extra gain at the spine, total hip or total body [18].

FDA's overall read of these trials lists hyperglycemia, liver enzyme elevations, edema and fluid overload, and congestive heart failure in elderly hip-fracture patients among the serious concerns, plus musculoskeletal pain, increased appetite and raised prolactin [2].

If the Goal Is a Tendon, Ligament or Gut Problem

BPC-157 has limited human reports on knee pain and bladder symptoms, plus an ulcerative-colitis trial reported only as a meeting abstract. These do not establish that it heals tendons, ligaments or the gut [1][11][12]. In the knee-injection chart review, 11 of the 12 patients who received BPC-157 alone reported significant improvement, with no control group and recalled results [11]. The 53-person ulcerative-colitis trial is larger, but FDA said the abstract has too little detail to judge effectiveness [1]. MK-677's trials reported body composition, physical function, cognition and safety labs, not tendon, ligament or gut healing [14][15][16].

If the Goal Is IGF-1 or Body Composition

MK-677 is the one with measured effects: in older adults over a year, fat-free mass rose 1.1 kg with MK-677 and fell 0.5 kg with placebo, while strength and function did not improve [14]. In obese men over 8 weeks, IGF-1 rose roughly 40% with a fat-free mass gain [17]. The same trials recorded higher fasting glucose, lower insulin sensitivity, edema, increased appetite and impaired glucose tolerance [14][16][17]. BPC-157's human reports concerned knee pain, bladder symptoms and safety bloodwork rather than IGF-1 or body composition [11][12][13].

If the Goal Is Both

No human study described on this page tested the two together, so their combined effects are unknown. MK-677 is an oral ghrelin-receptor agonist with a heart-failure signal in elderly hip-fracture patients and glucose and fluid-retention findings in several trials [5][2][14]. For BPC-157, FDA could not tell whether it caused the three reported adverse events, and its clotting-time and liver-enzyme findings came from animal studies [1].

Safety Points That Matter More Than the Stack Question

For MK-677, FDA's stated reason for its category 2 listing is the 'potential for congestive heart failure in certain patients', citing the hip-fracture trial terminated early for that signal [4][5]. FDA's review folds in class-wide growth hormone and IGF-1 risks seen on approved growth hormone labels: increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, pancreatitis, and in children slipped capital femoral epiphysis and scoliosis progression [2]. It also notes there are no long-term safety data in the older adults the drug is marketed to, and that higher IGF-1 appears linked to cancer risk across ages [2]. The 2004 hip-fracture trial excluded people with congestive heart failure, uncontrolled hypertension, diabetes or cancer from enrollment [15].

For BPC-157, FDA's stated concerns about compounded product are immunogenicity risk for certain routes, peptide-related impurities, characterization of the active ingredient, and that FDA 'has identified no, or only limited, safety-related information for the proposed routes of administration' [4].

Regulatory Status and Sport

No US Pharmacopeia or National Formulary monograph exists for BPC-157, no approved drug contains it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. It sat in FDA's category 2 from September 2023 until April 22, 2026, then moved to a 'nominated but withdrawn' table after the nominating groups withdrew; the move was not a finding of safety, and it is not in category 1, so FDA's category 1 enforcement discretion does not cover it [4][6]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it to FDA's bulks list, against FDA staff's recommendation; the vote is advice only and the substance is not on the list [19][20][1]. HHS filed a draft enforcement-discretion policy on October 28, 2026 covering six peptides including BPC-157 acetate in subcutaneous, intramuscular, oral and topical forms. It applies to state-licensed pharmacies, federal facilities and licensed physicians, with conditions such as a single active ingredient, bulk substance from an FDA-registered manufacturer with a certificate of analysis, a patient-specific prescription and MedWatch reporting; it is not an approval and is not binding [8][20]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [20].

MK-677 is in FDA's category 2, added December 29, 2022 for outsourcing facilities and September 29, 2023 for state-licensed pharmacies and physicians, and still listed as of the April 22, 2026 page [4][6][21]. On October 29, 2024 the advisory committee voted 1 yes and 13 no against adding ibutamoren mesylate to the bulks list [22]. It is not among the six peptides in the HHS draft policy [8]. In a December 12, 2025 warning letter, FDA stated that ibutamoren is excluded from the dietary supplement definition and that products marketed with drug claims are unapproved new drugs [23]; a September 23, 2025 FDA notice found unlabeled ibutamoren in a children's growth formula and listed the risks it may carry [24].

In sport, WADA names BPC-157 in S0 (non-approved substances) and ibutamoren in S2.2.4 (growth hormone secretagogues). Both are prohibited at all times, in and out of competition, on the 2026 List in force since January 1, 2026 [7].

Doses Used in Studies, Not Recommendations

There is no approved dose of either compound. Adult MK-677 trials used 2 mg to 50 mg per day, most often 25 mg once daily, for up to 2 years, with 0.2 to 0.8 mg/kg/day used in children [2]. The small BPC-157 human reports used 2 to 4 mg injected into the knee once or twice, 10 mg injected around the bladder wall once, 10 mg then 20 mg intravenously on two days, 80 mg daily as a rectal enema for 2 weeks, and up to 2 mg/kg daily by enema for 8 days in healthy volunteers [1].